OPS: Metodología: Lista de Dispositivos Médicos Prioritarios en el contexto de COVID-19
Metodología: Lista de Dispositivos Médicos Prioritarios en el contexto de COVID-19
Haga clic aquí
OPAS: Lista de medicamentos esenciales para el manejo de pacientes que ingresan a unidades de cuidados intensivos con sospecha o diagnóstico confirmado de COVID-19
Lista de medicamentos esenciales para el manejo de pacientes que ingresan a unidades de cuidados intensivos con sospecha o diagnóstico confirmado de COVID-19 [Es]
Haga clic aquí
[Ensayos clínicos de reposicionamiento de medicamentos para el tratamiento de la COVID-19]
Pan American Journal of Public Health: Recently published articles / NEW info on COVID-19 for authors and readers
[Ensayos clínicos de reposicionamiento de medicamentos para el tratamiento de la COVID-19]
Sandro Rosa and Wilson Santos
Brief communication l Published March 20 2020 l https://doi.org/10.26633/RP
[No hay evidencia que avale el uso de éter y cloroformo por vía inhalatoria para el tratamiento de la COVID-19]
Pan American Journal of Public Health: Recently published articles / NEW info on COVID-19 for authors and readers
[No hay evidencia que avale el uso de éter y cloroformo por vía inhalatoria para el tratamiento de la COVID-19]
Paulo Ricardo Martins-Filho and Victor Santana Santos
Letter to the editor l Published March 24 2020 l https://doi.org/10.26633/RPSP.2020.41
WHO: Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19)
This document provides interim guidance on the management of the blood supply in response to the pandemic outbreak of coronavirus disease (COVID-19). It is intended for blood services, national health authorities, and others responsible for the provision of blood and blood components and integration of the blood system within the public health system. WHO will continue to update this guidance as new information becomes available.
Please, go to https://apps.who.int/iris/rest/bitstreams/1272656/retrieve
REFERENCE NUMBERS
OPAS: Pesquisa clínicas de reposicionamento de medicamentos para o tratamento com COVID-19
The World Health Organization (WHO) was informed in December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus Betacoronavirus, that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants’ clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution.
FDA alerta os consumidores sobre os kits de teste não autorizados e fraudulentos do COVID-19
- A notícia abaixo está disponível somente no idioma original (inglês)
-
-
Coronavirus (COVID-19) Update: FDA Alerts Consumers About Unauthorized Fraudulent COVID-19 Test Kits
-
- Statement From:
-
Commissioner of Food and Drugs – Food and Drug Administration
Stephen M. Hahn M.D.
Associate Commissioner for Regulatory Affairs – Office of Regulatory AffairsJudith A. McMeekin Pharm.D.
The U.S. Food and Drug Administration is actively and aggressively monitoring the market for any firms marketing products with fraudulent coronavirus (COVID-19) diagnostic, prevention and treatment claims as part of our ongoing efforts to protect public health during this pandemic. As a result of these activities, the agency is beginning to see unauthorized fraudulent test kits that are being marketed to test for COVID-19 in the home.
For more information go to
OPAS: Anuncio sobre o ibuprofen e COVID-19 (es)
En síntesis y hasta que se generen evidencias adicionales, creemos adecuada la aproximación sugerida por el NHS de UK, que reconociendo la falta de pruebas respecto de efectos perjudiciales del ibuprofeno en infecciones por COVID-19 no aconseja suspender tratamientos con este medicamento, pero en caso de iniciarlos prioriza el uso de paracetamol para tratar los síntomas de la infección.
European Medicine Agency (EMA) gives advice on the use of non-steroidal anti-inflammatories for COVID-19
European Medicine Agency (EMA) is aware of reports, especially on social media, which raise questions about whether non-steroidal anti-inflammatory medicines (NSAIDs) such as ibuprofen could worsen coronavirus disease (COVID-19).
There is currently no scientific evidence establishing a link between ibuprofen and worsening of COVID‑19. EMA is monitoring the situation closely and will review any new information that becomes available on this issue in the context of the pandemic.
For more information go to https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19
